July - September 2018, Volume 14, Issue 3

Trifanescu OG, Gales LN, Trifanescu RA, Anghel RM

Clinical Prognostic Factors in pre-and Post-Menopausal Women with Ovarian Carcinoma

Acta Endo (Buc) 2018, 14 (3): 353-359
doi: 10.4183/aeb.2018.353

Aims. To assess the impact of prognostic factors on the outcome of ovarian carcinoma (OC) and to determine the difference between pre and postmenopausal patients. Design. Retrospective cohort, single centre study Subjects and Methods. One-hundred-sixty patients with stage IC-IV OC diagnosed between 2004-2016 were included. Treatment consisted in primary surgery followed by adjuvant chemotherapy (n=127, 79.4%), neoadjuvant chemotherapy followed by surgery (n=27, 16.9%) and chemotherapy alone (3.7%). Results. At diagnosis 62 patients (38.8%) were premenopausal. Most patients presented with advanced OC (stage III/IV, 63.1%). After a median follow-up of 60 months, median progression free survival (PFS) for all stages was 36 months and median overall survival (OS) was 96 months. Postmenopausal patients had a poorer oncologic outcome compared with pre-menopausal women (PFS 24 vs. 72 months, p=0.0001, HR=2.32). Other clinical prognostic factors identified were performance status 1 vs. 0 (p=0.0001), ascites (p=0.027). Pathology prognostic factors were tumour grade (G1 vs. G2 and G3, p=0.0001) and endometrioid subtype compared to serous (p=0.008). Patients with residual disease after surgery had an increased risk of recurrence and death (HR=6.1, p=0.0001 and HR=4.2, p=0.0001). Conclusion. Premenopausal patients had a better oncologic long-term outcome and stage, ascites, grading, residual disease, were independent prognostic factors.

Keywords: prognostic, menopause, residual disease, ovarian carcinoma

Correspondence: Raluca Alexandra Trifanescu MD, “Carol Davila” University, Dept. of Endocrinology, “C. I. Parhon” Institute of Endocrinology, 34-36 Aviatorilor blvd., Bucharest, 011863, Romania, E-mail: ralucatrifanescu@yahoo.com